Oruka Therapeutics, Inc. (ORKA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oruka Therapeutics, Inc. (ORKA) has a cash flow conversion efficiency ratio of -0.044x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.60 Million) by net assets ($486.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Oruka Therapeutics, Inc. (ORKA) balance sheet quality index to measure how much of total assets are equity-financed.
Oruka Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Oruka Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Oruka Therapeutics, Inc. strategic investment ratio to see how much of total assets are deployed in long-term investments.
Oruka Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oruka Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solvac S.A.
BR:SOLV
|
0.011x |
|
Bonesupport Holding AB
ST:BONEX
|
0.085x |
|
Mesoblast Limited
F:LWB
|
-0.028x |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
-0.028x |
|
Pharma Mar S.A.
MC:PHM
|
0.133x |
|
DRDGOLD Limited
JSE:DRD
|
0.251x |
|
Holmen AB (publ)
ST:HOLM-A
|
0.023x |
|
Central Securities Corporation
NYSE MKT:CET
|
0.006x |
Annual Cash Flow Conversion Efficiency for Oruka Therapeutics, Inc. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Oruka Therapeutics, Inc. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Oruka Therapeutics, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $382.22 Million | $-57.84 Million | -0.151x | +42.21% |
| 2022-12-31 | $41.67 Million | $-10.91 Million | -0.262x | +28.76% |
| 2021-12-31 | $51.04 Million | $-18.76 Million | -0.368x | -121.36% |
| 2020-12-31 | $46.52 Million | $-7.72 Million | -0.166x | +73.68% |
| 2019-12-31 | $7.61 Million | $-4.80 Million | -0.631x | +53.84% |
| 2018-12-31 | $6.03 Million | $-8.24 Million | -1.367x | +19.63% |
| 2017-12-31 | $10.28 Million | $-17.47 Million | -1.700x | -151.82% |
| 2016-12-31 | $22.19 Million | $-14.99 Million | -0.675x | -144.04% |
| 2015-12-31 | $38.07 Million | $-10.53 Million | -0.277x | +56.64% |
| 2014-12-31 | $14.74 Million | $-9.41 Million | -0.638x | -88.01% |
| 2013-12-31 | $15.58 Million | $-5.29 Million | -0.339x | +75.81% |
| 2012-12-31 | $2.91 Million | $-4.08 Million | -1.403x | -15.55% |
| 2011-12-31 | $5.73 Million | $-6.96 Million | -1.214x | +1.24% |
| 2010-12-31 | $6.77 Million | $-8.32 Million | -1.229x | +78.16% |
| 2009-12-31 | $7.41 Million | $-41.73 Million | -5.630x | -262.54% |
| 2008-12-31 | $-5.31 Million | $-18.40 Million | 3.463x | +609.88% |
| 2007-12-31 | $67.66 Million | $-45.96 Million | -0.679x | -28.01% |
| 2006-12-31 | $69.84 Million | $-37.06 Million | -0.531x | +48.98% |
| 2005-12-31 | $56.76 Million | $-59.03 Million | -1.040x | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-1… Read more